UK investigates GlaxoSmithKline over "pay to delay" allegations

04/24/2013 | Ventura County Star (Calif.) (free registration)

The U.K. Office of Fair Trading is investigating allegations that GlaxoSmithKline has been paying competitors to delay market entry of their own versions of the GSK antidepressant Seroxat. If the watchdog agency decides that GSK was in violation, the drugmaker could be liable for fines of up to 30% of revenue during the period that the payments were made. "GSK supports fair competition and we very strongly believe that we acted within the law," the company said in a statement, vowing to cooperate fully in the investigation.

View Full Article in:

Ventura County Star (Calif.) (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Actuary
Meridian Health Plan
Detroit, MI
Director, Payer Marketing
Avalere Health
Washington, DC
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Children's Health Plan
Houston, TX
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX